841
Participants
Start Date
November 15, 2021
Primary Completion Date
April 4, 2024
Study Completion Date
May 28, 2024
Upadacitinib
Hold UPA x 2 weeks at time of COVID booster
Abatacept
Hold SQ ABA x 2 weeks at time of COVID booster
Secukinumab
Hold SEC x 2 weeks at time of COVID booster
Tofacitinib
Hold TOF x 2 weeks at time of COVID booster
TNF Inhibitor
Hold SQ TNFi x 2 weeks at time of COVID booster
Canakinumab Injection
Hold CAN TNFi x 2 weeks at time of COVID booster
Baricitinib
Hold BAR x 2 weeks at time of COVID booster
Ixekizumab
Hold IXE x 2 weeks at time of COVID booster
University of Pennsylvania Medical Center, Philadelphia
Illumination Health/Bendcare, Hoover
Rheumatology Care Center, Hoover
University of Alabama at Birmingham, Birmingham
University of Nebraska Medical Center, Omaha
Metroplex Clinical Research Center, Dallas
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix
Attune Health, Beverly Hills
Collaborators (5)
University of Alabama at Birmingham
OTHER
University of Nebraska
OTHER
University of Pennsylvania
OTHER
AbbVie
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Novartis
INDUSTRY
Eli Lilly and Company
INDUSTRY
Pfizer
INDUSTRY
Illumination Health
NETWORK
Jeffrey Curtis
OTHER